For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Tscan Therapeutics Inc (NASDAQ: TCRX) was $5.94 for the day, up 4.39% from the previous closing price of $5.69. In other words, the price has increased by $4.39 from its previous closing price. On the day, 0.53 million shares were traded. TCRX stock price reached its highest trading level at $6.225 during the session, while it also had its lowest trading level at $5.72.
Ratios:
Our analysis of TCRX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 7.77 and its Current Ratio is at 7.77. In the meantime, Its Debt-to-Equity ratio is 0.36 whereas as Long-Term Debt/Eq ratio is at 0.30.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on May 16, 2024, initiated with a Buy rating and assigned the stock a target price of $12.
On May 13, 2024, Needham started tracking the stock assigning a Buy rating and target price of $11.
On June 22, 2023, Wedbush started tracking the stock assigning a Outperform rating and target price of $8.Wedbush initiated its Outperform rating on June 22, 2023, with a $8 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 23 ’24 when Klencke Barbara bought 5,000 shares for $5.29 per share. The transaction valued at 26,450 led to the insider holds 45,000 shares of the business.
Klencke Barbara bought 5,000 shares of TCRX for $28,450 on Aug 23 ’24. The Director now owns 35,000 shares after completing the transaction at $5.69 per share. On Aug 26 ’24, another insider, Klencke Barbara, who serves as the Director of the company, bought 5,000 shares for $5.53 each. As a result, the insider paid 27,650 and bolstered with 40,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TCRX now has a Market Capitalization of 314664960 and an Enterprise Value of 108061784. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.79 while its Price-to-Book (P/B) ratio in mrq is 1.23. Its current Enterprise Value per Revenue stands at 8.858 whereas that against EBITDA is -1.013.
Stock Price History:
Over the past 52 weeks, TCRX has reached a high of $9.69, while it has fallen to a 52-week low of $3.73. The 50-Day Moving Average of the stock is 11.09%, while the 200-Day Moving Average is calculated to be -10.19%.
Shares Statistics:
TCRX traded an average of 219.88K shares per day over the past three months and 292270 shares per day over the past ten days. A total of 43.55M shares are outstanding, with a floating share count of 41.65M. Insiders hold about 21.37% of the company’s shares, while institutions hold 78.77% stake in the company. Shares short for TCRX as of 1728950400 were 2244117 with a Short Ratio of 10.21, compared to 1726185600 on 1796710. Therefore, it implies a Short% of Shares Outstanding of 2244117 and a Short% of Float of 5.87.
